Dergiler / Bezmiâlem Science / 2018 / Cilt: 6 - Sayı: 3

Are There Any Systemic Effects of the Intratympanic Administration of Dexamethasone?

İntratimpanik Deksametazonun Sistemik Etkisi Var mı?

Sayfa
186–190
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: This study shows that intratympanic steroids have no noticeable systemic steroidal side effects and are therefore safe to use; however, caution should be taken with patients suffering from diabetes mellitus, and they should be closely monitored.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Systemic absorption of steroids is reasonable because of the lipophilic nature of steroids and high vascularity of the middle ear mucosa.
📊
Temel Bulgular & Veri:This study aims to demonstrate whether the intratympanic administration of dexa- methasone has any systemic effects.
💡
Sonuç & Katkı:Conclusion: This study shows that intratympanic steroids have no noticeable systemic steroidal side effects and are therefore safe to use; however, caution should be taken with patients suffering from diabetes mellitus, and they should be closely monitored.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: Systemic absorption of steroids is reasonable because of the lipophilic nature of steroids and high vascularity of the middle ear mucosa. To date, however, of the clinical trials de- signed to investigate this subject, to the best of our knowledge, none has been based on objective methods. This study aims to demonstrate whether the intratympanic administration of dexa- methasone has any systemic effects. Methods: Seventeen patients had a total of five sessions of in- tratympanic dexamethasone treatment scheduled for every other day. The mean fasting blood glucose, serum cortisol, serum adre- nocorticotrophic hormone (ACTH), and arterial blood pressure values of the patients were checked at each session before and after drug application. Result: There were no statistically significant differences identi- fied between the pre- and post-treatment fasting blood glucose, serum cortisol, serum ACTH, and mean arterial blood pressure. Conclusion: This study shows that intratympanic steroids have no noticeable systemic steroidal side effects and are therefore safe to use; however, caution should be taken with patients suffering from diabetes mellitus, and they should be closely monitored.

Abstract

Amaç: Orta kulak mukozasının hipervaskülasrizasyonu ve stero- idlerin lipofilik yapısı dikkate alındığında, steroidlerin sisstemik absorbsiyonu düşünülmelidir. Fakat günümüze kadar yapılan klinik çalışmalarda bu absorbsiyonun etkisi objektif olarak de- ğerlendirilememiştir. Bu çalışmanın amacı intratimpanik dexa- metazon uygulamasının sistemik etkilerini olup olmadığını in- celemektir. Yöntemler: İntratimpanik deksametazon tedavisi planlanan 17 hastaya iki gün arayla toplam 5 defa intratimpanik steroid yapıl- dı. Hastaların uygulama öncesi ve sonrası açlık kan şekeri, serum kortizol, serum ACTH (adrenocorticotrophic hormone) değerle- rine ve arteryel tansiyonlarına bakıldı. Bulgular: Hastaların intratimpanik tedavi öncesi ve sonrası açlık kan şekeri, serum kortizol, serum ACTH ve tansiyon arteryelle- rinde istatistiksel olarak anlamlı bir fark saptanmadı. Sonuç: İntratimpanik steroid, anlamlı bir sistemik yan etki oluş- turmamaktadır ve güvenlidir, ancak yine de DM olan hastalarda dikkat edilmesi ve yakın takip edilmesi gereklidir.

🔖

Bu Makaleye Atıf Yap

ŞENTÜRK, E., TUĞRUL, S., YILDIRIM, Y. S., DOĞAN, R., EREN, S. B., ÖZTURAN, O. (2018). Are There Any Systemic Effects of the Intratympanic Administration of Dexamethasone?. Bezmiâlem Science, Cilt: 6 - Sayı: 3, 186–190. https://ajindex.com/articles/150946

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (2)

  1. McCabe BF. Autoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol 1979; 88: 585-9. [CrossRef ] McCabe BF. Autoimmune inner ear disease: results of therapy. Adv Otorhinolaryngol 1991; 46: 78-81. [CrossRef ] Harris JP. Experimental immunology of the inner ear. Adv Oto- rhinolaryngol 1991; 46: 26-33. [CrossRef ] Hughes GB, Kinney SE, Barna BP, Calabrese LH. Practical ver- sus theoretical management of autoimmune inner ear disease. Laryngoscope 1984; 94: 758-66. [CrossRef ] Chandrasekhar SS, Rubinstein RY, Kwartler JA, Gatz M, Con- nelly PE, Huang E, et al. Dexamethasone pharmacokinetics in the inner ear: Comparison of route of administration and use of facilitating agents. Otolaryngol Head Neck Surg 2000; 122: 521-8. [CrossRef ] Parnes LS, Sun AH, Freeman DJ. Corticosteroid pharmacoki- netics in the inner ear fluids: an animal study followed by clini- cal application. Laryngoscope 1999; 109: 1-17. [CrossRef ] Plontke SKR, Salt AN. Quantitative interpretation of cortico- steroid pharmacokinetics in inner fluids using computer simu- lations. Hear Res 2003; 182: 34-42. [CrossRef ] Bachmann G, Su J, Zumegen C, Wittekindt C, Michel O. Per- meabilitat der runden fenster membran fur prednisolon-21-hy- drogensuccinat. HNO 2001; 49: 538-42. [CrossRef ] Kakehata S, Sasaki A, Oji K, Futai K, Ota S, Makinae K, et al. Comparison of intratympanic and intravenous dexamethasone treatment on sudden sensorineural hearing loss with diabetes. Otol Neurotol 2006; 27: 604-8. [CrossRef ] Han CS, Park JR, Boo SH, Jo JM, Park KW, Lee WY, et al. Clinical efficacy of initial intratympanic steroid treatment on sudden sensorineural hearing loss with diabetes. Otolaryngol Head Neck Surg 2009; 141: 572-8. [CrossRef ] Gallegos-Constantino V, Cervera-Paz FJ, Salvador J, Ba FK, Perez-Fernandez N. Hyperglycemia after intratympanic dexa- methasone treatment in a diabetic patient. Rev Laryngol Otol Rhinol (Bord) 2011; 132: 153-5.
  2. Yuen KC, McDaniel PA, Riddle MC. Twenty-fourhour pro- files of plasma glucose, insulin, C-peptide and free fatty acid in subjects with varying degrees of glucose tolerance following short-term medium-dose prednisone (20 mg/day) treatment: evidence for differing effects on insulin secretion. Clin Endo- crinol 2012; 77: 224-32. [CrossRef ] 190 Van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 2009; 39: 81-93. [CrossRef ] Hargunani CA, Kempton B, DeGagn